Detalles de la búsqueda
1.
A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
Clin Cancer Res
; 14(7): 2075-81, 2008 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18381947
2.
CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Clin Cancer Res
; 11(14): 5281-91, 2005 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16033847
3.
SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.
FASEB J
; 16(7): 681-90, 2002 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-11978732
4.
An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.
Clin Cancer Res
; 9(15): 5465-76, 2003 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-14654525
5.
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
Clin Cancer Res
; 9(1): 327-37, 2003 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-12538485
6.
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Leuk Res
; 28(7): 679-89, 2004 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-15158089
7.
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.
Clin Cancer Res
; 20(17): 4488-98, 2014 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24687921
8.
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Blood
; 105(3): 986-93, 2005 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15459012
9.
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
Blood
; 101(9): 3597-605, 2003 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12531805
10.
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood
; 102(3): 795-801, 2003 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12649163
Resultados
1 -
10
de 10
1
Próxima >
>>